Kairos Pharma, LTD. KAPA
Kairos Pharma, LTD. (NYSE: KAPA) is an oncology drug developer. Its lead program, ENV 105 (carotuximab), is in Phase 2 for Androgen-therapy-resistant castrate-resistant prostate cancer (with apalutamide).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ENV 105 | Castrate-resistant prostate cancer, randomized Phase 2 with apalutamide | antibody | Phase 2 |
| ENV 105 | EGFR-resistant non-small cell lung cancer, Phase 1 with osimertinib | antibody | Phase 1 |
| KROS 201 | Recurrent glioblastoma (activated T cell therapy) | cell therapy | Phase 1 |
| KROS 101 | Solid tumors (GITR ligand small molecule) | small molecule | Pre-clinical |
| KROS 102 | Autoimmune diseases (GITR antagonist) | small molecule | Pre-clinical |
| KROS 301 | RelA-positive solid tumors | small molecule | Pre-clinical |
| KROS 401 | Triple negative breast cancer / tumor microenvironment | protein/peptide | Pre-clinical |
| ENV 205 | Chemotherapy-resistant prostate cancer / cachexia | antibody | Pre-clinical |
Recent results and decisions
- Nov 5, 2026positive ENV-105 plus apalutamide showed statistically significant improvement in progression-free survival compared to apalutamide alone in interim Phase 2 analysis for metastatic castration-resistant prostate cancer.
The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all patients in the trial treated with ENV-105 plus apalutamide and those treated with apalutamide alone.
Filing - Nov 3, 2026met ENV-105 plus apalutamide demonstrated statistically significant improvement in progression-free survival versus apalutamide alone in mCRPC interim analysis.
The positive interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all patients in the trial treated with ENV-105 plus apalutamide and those treated with apalutamide alone.
Filing - Oct 6, 2026positive Interim Phase 2 analysis: median PFS 17.7 months with ENV-105 plus apalutamide vs 2 months with apalutamide alone, P=0.0008.
Median PFS was 17.7 months with the combination compared with 2 months with apalutamide alone (P=0.0008).
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.